HBX 41108
(Synonyms: 7-氯-9-氧代-9H-茚并[1,2-B]吡嗪-2,3-二甲腈) 目录号 : GC12622
An inhibitor of USP7
Cas No.:924296-39-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1, 2]: | |
|
Cell lines |
HCT116 colon cancer cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
24 h |
|
Applications |
In HCT116 colon cancer cells, treated with various doses of HBX 41,108 (1, 3, and 10 μmol/L) for 24 h increased p53 levels in a nongenotoxic manner. HBX 41,108 inhibited USP7 activity in HEK293 cells transfected with USP7. HBX 41,108 (0.1-10 μM, 24 h) inhibited HCT116 cancer cell growth and induced apoptotic cell death. HBX 41,108 induced p53-dependent apoptosis in p53 wild-type and null isogenic cancer cell lines. In COS7 cells, HBX 41108 inhibited PPARγ stability induced by USP7 and decreased the basal transcriptional activity of PPARγ by 70%。 |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther, 2009, 8(8): 2286-2295. [2]. Lee KW, Cho JG, Kim CM, et al. Herpesvirus-associated Ubiquitin-specific Protease (HAUSP) Modulates Peroxisome Proliferator-activated Receptor γ (PPARγ) Stability through Its Deubiquitinating Activity. J Biol Chem, 2013, 288(46): 32886-32896. |
|
HBX 41108 is a potent inhibitor of USP7 with IC50 value of 424 nM [1].
Ubiquitin-specific-processing protease 7 (USP7) is a ubiquitin specific protease and removes ubiquitin from specific protein substrates. USP7 can deubiquitinate p53, protecting p53 from Mdm2-mediated degradation and involving the oncogenic stabilization of p53.
HBX 41108 is an uncompetitive and reversible USP7 inhibitor. HBX 41108 inhibited USP7-mediated p53 deubiquitination with IC50 value of 0.8 μM in a dose-dependent way and was only weakly active against the aspartic, serine and metalloproteases tested with IC50 > 10 μM. In HCT116 cells, HBX 41108 increased the levels of p53 and p21cip1/waf, which was the product of p53 target genes. In HEK293 cells, HBX 41108 increased the level of polyubiquitinated forms of p53 and reduced Mdm2 levels. In HCT116 colon cancer cells, HBX 41108 inhibited cell proliferation with IC50 value of 1 μM in a dose-dependent way and induced apoptosis in a dose-dependent manner [1]. In COS7 cells, HBX 41108 inhibited PPARγ stability induced by USP7 and decreased the basal transcriptional activity of PPARγ by 70% [2].
References:
[1]. Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther, 2009, 8(8): 2286-2295.
[2]. Lee KW, Cho JG, Kim CM, et al. Herpesvirus-associated Ubiquitin-specific Protease (HAUSP) Modulates Peroxisome Proliferator-activated Receptor γ (PPARγ) Stability through Its Deubiquitinating Activity. J Biol Chem, 2013, 288(46): 32886-32896.
| Cas No. | 924296-39-9 | SDF | |
| 别名 | 7-氯-9-氧代-9H-茚并[1,2-B]吡嗪-2,3-二甲腈 | ||
| 化学名 | 7-chloro-9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile | ||
| Canonical SMILES | ClC1=CC=C(C2=NC(C#N)=C(C#N)N=C2C3=O)C3=C1 | ||
| 分子式 | C13H3ClN4O | 分子量 | 266.64 |
| 溶解度 | 33mg/mL in DMSO; 25mg/mL in DMF; | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7504 mL | 18.7519 mL | 37.5038 mL |
| 5 mM | 0.7501 mL | 3.7504 mL | 7.5008 mL |
| 10 mM | 0.375 mL | 1.8752 mL | 3.7504 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。